Ventures
Invest in breakthrough healthtech solutions that transform patients' lives.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.
a highlight from our portfolio

Angiogenesis Analytics

PEP Health
Sigilla Medical is developing an innovative, implant-free radiofrequency device designed to close PFOs (patent foramen ovale) in stroke-risk patients. PFOs are associated with cryptogenic stroke and migraine, and current treatment involves placing a large metal device that spans the septum of the heart in an otherwise young and healthy patient. Sigilla’s device offers a safer, more efficient alternative by using controlled radiofrequency to seal the PFO without the need for implants. This less-invasive approach reduces procedural risk and adverse cardiac events while leaving options open for future minimally invasive procedures.

AIDO enhances precision control during endoscopic procedures with its drive unit. Physicians can now maintain control of the endoscope shaft while operating tools, saving time and improving efficiency. This platform technology streamlines the control of instruments inserted through the endoscope's working channel, offering automatic insertion and precise control, ultimately improving patient safety and procedural outcomes.

Wavefront is revolutionizing live-cell imaging with their AI-driven computational microscope, offering a stain-free imaging technique powered by patented quantitative-phase-imaging (QPI) technology. This approach eliminates the need for costly and invasive chemical staining, preserving cell integrity with real-time visualization of cellular structures with precision and detail. Wavefront's innovative solution has transformative potential research across diverse fields, from cancer research to clinical diagnostics.

Porous GmbH has developed an ultrasound technology that accurately diagnoses cortical bone health, addressing the limitations of traditional methods. Osteoporosis affects millions globally, leading to frequent and costly fractures. Current diagnostics often miss early-stage bone deterioration, but Porous GmbH’s patented algorithms allow ultrasound to measure bone quality at a microscopic level for a safer and more precise method for early detection of osteoporosis, also reducing healthcare costs.

Aetherus tackles COPD, a debilitating lung disease, with their portable, non-invasive (pNIV) device. This device offers instant relief from breathlessness, improving patients' daily lives without adding to treatment regimens or causing side effects. By empowering patients to manage breathlessness anytime, anywhere, the pNIV device enhances COPD management and quality of life. This not only benefits patients but also alleviates the burden on healthcare systems, families, employers, and society at large.

StarTric, created by cardiovascular experts, developed a new, less invasive device to fix a serious heart valve problem, Tricuspid Regurgitation (TR). Addressing Tricuspid Regurgitation (TR), a severe condition with high mortality rates, StarTric's device offers a safer alternative to open-heart surgery. The technology can be implanted via a transfemoral catheter, combining the safety of minimally invasive methods with the proven efficacy of the Clover technique, aiming to provide effective treatment to millions of TR patients worldwide who currently lack suitable options.
.webp)
ProVascTec offers a novel solution for chronic arterial disease, focusing on peripheral arterial disease (PAD) and chronic limb ischemia. Unlike traditional treatments like angioplasty or bypass surgery, ProVascTec aims to stimulate vascular tissue growth using mesenchymal stem cells, reducing complications and improving blood flow. This innovative approach has the potential to benefit millions of patients suffering from PAD worldwide.

Haermonics addresses the challenge of complications after open heart surgery with a transformative solution. Excessive blood loss and clots post-surgery lead to numerous issues, including reoperations and cardiac tamponades, resulting in significant healthcare costs and loss of lives. The Haermonics Flush device offers a preventive approach by flushing the pericardial cavity after surgery, limiting blood loss and clot formation. By providing medical professionals with better patient status monitoring, Haermonics Flush empowers doctors to make more informed decisions, ultimately saving thousands of lives and billions in hospital costs.

Our impact
Explore our 2024 Impact report

Invest in a portfolio of companies





